Pharma & Healthcare
Global HAE Treatments Market Outlook, In‑Depth Analysis & Forecast to 2031
- Oct 16, 25
- ID: 552820
- Pages: 125
- Figures: 118
- Views: 11
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global HAE Treatments market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Takeda Pharmaceuticals
BioCryst Pharmaceuticals
CSL Behring
Pharming Healthcare
Segment by Type
C1 Esterase Inhibitors
Kallikrein Inhibitors
Bradykinin Receptor Antagonist
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the HAE Treatments study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global HAE Treatments market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Takeda Pharmaceuticals
BioCryst Pharmaceuticals
CSL Behring
Pharming Healthcare
Segment by Type
C1 Esterase Inhibitors
Kallikrein Inhibitors
Bradykinin Receptor Antagonist
Segment by Application
Hospital and Clinic
Pharmacy
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the HAE Treatments study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to HAE Treatments: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HAE Treatments Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 C1 Esterase Inhibitors
1.2.3 Kallikrein Inhibitors
1.2.4 Bradykinin Receptor Antagonist
1.3 Market Segmentation by Application
1.3.1 Global HAE Treatments Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HAE Treatments Revenue Estimates and Forecasts 2020-2031
2.2 Global HAE Treatments Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global HAE Treatments Sales Estimates and Forecasts 2020-2031
2.4 Global HAE Treatments Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global HAE Treatments Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global HAE Treatments Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 C1 Esterase Inhibitors Market Size by Manufacturers
3.5.2 Kallikrein Inhibitors Market Size by Manufacturers
3.5.3 Bradykinin Receptor Antagonist Market Size by Manufacturers
3.6 Global HAE Treatments Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global HAE Treatments Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global HAE Treatments Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global HAE Treatments Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HAE Treatments Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America HAE Treatments Sales and Revenue by Type (2020-2031)
6.4 North America HAE Treatments Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America HAE Treatments Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe HAE Treatments Sales and Revenue by Type (2020-2031)
7.4 Europe HAE Treatments Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe HAE Treatments Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific HAE Treatments Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific HAE Treatments Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific HAE Treatments Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America HAE Treatments Sales and Revenue by Type (2020-2031)
9.4 Central and South America HAE Treatments Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America HAE Treatments Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa HAE Treatments Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa HAE Treatments Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa HAE Treatments Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Business Overview
11.1.3 Takeda Pharmaceuticals HAE Treatments Product Models, Descriptions and Specifications
11.1.4 Takeda Pharmaceuticals HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Takeda Pharmaceuticals HAE Treatments Sales by Product in 2024
11.1.6 Takeda Pharmaceuticals HAE Treatments Sales by Application in 2024
11.1.7 Takeda Pharmaceuticals HAE Treatments Sales by Geographic Area in 2024
11.1.8 Takeda Pharmaceuticals HAE Treatments SWOT Analysis
11.1.9 Takeda Pharmaceuticals Recent Developments
11.2 BioCryst Pharmaceuticals
11.2.1 BioCryst Pharmaceuticals Corporation Information
11.2.2 BioCryst Pharmaceuticals Business Overview
11.2.3 BioCryst Pharmaceuticals HAE Treatments Product Models, Descriptions and Specifications
11.2.4 BioCryst Pharmaceuticals HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 BioCryst Pharmaceuticals HAE Treatments Sales by Product in 2024
11.2.6 BioCryst Pharmaceuticals HAE Treatments Sales by Application in 2024
11.2.7 BioCryst Pharmaceuticals HAE Treatments Sales by Geographic Area in 2024
11.2.8 BioCryst Pharmaceuticals HAE Treatments SWOT Analysis
11.2.9 BioCryst Pharmaceuticals Recent Developments
11.3 CSL Behring
11.3.1 CSL Behring Corporation Information
11.3.2 CSL Behring Business Overview
11.3.3 CSL Behring HAE Treatments Product Models, Descriptions and Specifications
11.3.4 CSL Behring HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 CSL Behring HAE Treatments Sales by Product in 2024
11.3.6 CSL Behring HAE Treatments Sales by Application in 2024
11.3.7 CSL Behring HAE Treatments Sales by Geographic Area in 2024
11.3.8 CSL Behring HAE Treatments SWOT Analysis
11.3.9 CSL Behring Recent Developments
11.4 Pharming Healthcare
11.4.1 Pharming Healthcare Corporation Information
11.4.2 Pharming Healthcare Business Overview
11.4.3 Pharming Healthcare HAE Treatments Product Models, Descriptions and Specifications
11.4.4 Pharming Healthcare HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pharming Healthcare HAE Treatments Sales by Product in 2024
11.4.6 Pharming Healthcare HAE Treatments Sales by Application in 2024
11.4.7 Pharming Healthcare HAE Treatments Sales by Geographic Area in 2024
11.4.8 Pharming Healthcare HAE Treatments SWOT Analysis
11.4.9 Pharming Healthcare Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 HAE Treatments Industry Chain
12.2 HAE Treatments Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HAE Treatments Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HAE Treatments Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 HAE Treatments Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global HAE Treatments Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to HAE Treatments: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HAE Treatments Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 C1 Esterase Inhibitors
1.2.3 Kallikrein Inhibitors
1.2.4 Bradykinin Receptor Antagonist
1.3 Market Segmentation by Application
1.3.1 Global HAE Treatments Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HAE Treatments Revenue Estimates and Forecasts 2020-2031
2.2 Global HAE Treatments Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global HAE Treatments Sales Estimates and Forecasts 2020-2031
2.4 Global HAE Treatments Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global HAE Treatments Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global HAE Treatments Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 C1 Esterase Inhibitors Market Size by Manufacturers
3.5.2 Kallikrein Inhibitors Market Size by Manufacturers
3.5.3 Bradykinin Receptor Antagonist Market Size by Manufacturers
3.6 Global HAE Treatments Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global HAE Treatments Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global HAE Treatments Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global HAE Treatments Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HAE Treatments Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America HAE Treatments Sales and Revenue by Type (2020-2031)
6.4 North America HAE Treatments Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America HAE Treatments Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe HAE Treatments Sales and Revenue by Type (2020-2031)
7.4 Europe HAE Treatments Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe HAE Treatments Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific HAE Treatments Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific HAE Treatments Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific HAE Treatments Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America HAE Treatments Sales and Revenue by Type (2020-2031)
9.4 Central and South America HAE Treatments Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America HAE Treatments Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa HAE Treatments Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa HAE Treatments Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa HAE Treatments Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Takeda Pharmaceuticals
11.1.1 Takeda Pharmaceuticals Corporation Information
11.1.2 Takeda Pharmaceuticals Business Overview
11.1.3 Takeda Pharmaceuticals HAE Treatments Product Models, Descriptions and Specifications
11.1.4 Takeda Pharmaceuticals HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Takeda Pharmaceuticals HAE Treatments Sales by Product in 2024
11.1.6 Takeda Pharmaceuticals HAE Treatments Sales by Application in 2024
11.1.7 Takeda Pharmaceuticals HAE Treatments Sales by Geographic Area in 2024
11.1.8 Takeda Pharmaceuticals HAE Treatments SWOT Analysis
11.1.9 Takeda Pharmaceuticals Recent Developments
11.2 BioCryst Pharmaceuticals
11.2.1 BioCryst Pharmaceuticals Corporation Information
11.2.2 BioCryst Pharmaceuticals Business Overview
11.2.3 BioCryst Pharmaceuticals HAE Treatments Product Models, Descriptions and Specifications
11.2.4 BioCryst Pharmaceuticals HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 BioCryst Pharmaceuticals HAE Treatments Sales by Product in 2024
11.2.6 BioCryst Pharmaceuticals HAE Treatments Sales by Application in 2024
11.2.7 BioCryst Pharmaceuticals HAE Treatments Sales by Geographic Area in 2024
11.2.8 BioCryst Pharmaceuticals HAE Treatments SWOT Analysis
11.2.9 BioCryst Pharmaceuticals Recent Developments
11.3 CSL Behring
11.3.1 CSL Behring Corporation Information
11.3.2 CSL Behring Business Overview
11.3.3 CSL Behring HAE Treatments Product Models, Descriptions and Specifications
11.3.4 CSL Behring HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 CSL Behring HAE Treatments Sales by Product in 2024
11.3.6 CSL Behring HAE Treatments Sales by Application in 2024
11.3.7 CSL Behring HAE Treatments Sales by Geographic Area in 2024
11.3.8 CSL Behring HAE Treatments SWOT Analysis
11.3.9 CSL Behring Recent Developments
11.4 Pharming Healthcare
11.4.1 Pharming Healthcare Corporation Information
11.4.2 Pharming Healthcare Business Overview
11.4.3 Pharming Healthcare HAE Treatments Product Models, Descriptions and Specifications
11.4.4 Pharming Healthcare HAE Treatments Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Pharming Healthcare HAE Treatments Sales by Product in 2024
11.4.6 Pharming Healthcare HAE Treatments Sales by Application in 2024
11.4.7 Pharming Healthcare HAE Treatments Sales by Geographic Area in 2024
11.4.8 Pharming Healthcare HAE Treatments SWOT Analysis
11.4.9 Pharming Healthcare Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 HAE Treatments Industry Chain
12.2 HAE Treatments Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HAE Treatments Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HAE Treatments Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 HAE Treatments Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global HAE Treatments Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global HAE Treatments Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global HAE Treatments Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global HAE Treatments Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global HAE Treatments Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global HAE Treatments Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global HAE Treatments Sales by Region (2020-2025) & (K Units)
Table 8. Global HAE Treatments Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global HAE Treatments Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global HAE Treatments Sales Share by Manufacturers (2020-2025)
Table 12. Global HAE Treatments Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global HAE Treatments Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global HAE Treatments by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HAE Treatments as of 2024)
Table 16. Global HAE Treatments Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global HAE Treatments Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers HAE Treatments Manufacturing Base and Headquarters
Table 19. Global HAE Treatments Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global HAE Treatments Sales by Type (2020-2025) & (K Units)
Table 23. Global HAE Treatments Sales by Type (2026-2031) & (K Units)
Table 24. Global HAE Treatments Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global HAE Treatments Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global HAE Treatments ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global HAE Treatments Sales by Application (2020-2025) & (K Units)
Table 29. Global HAE Treatments Sales by Application (2026-2031) & (K Units)
Table 30. HAE Treatments High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global HAE Treatments Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global HAE Treatments Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global HAE Treatments ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America HAE Treatments Growth Accelerators and Market Barriers
Table 37. North America HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe HAE Treatments Growth Accelerators and Market Barriers
Table 40. Europe HAE Treatments Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific HAE Treatments Growth Accelerators and Market Barriers
Table 45. Southeast Asia HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America HAE Treatments Investment Opportunities and Key Challenges
Table 47. Central and South America HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa HAE Treatments Investment Opportunities and Key Challenges
Table 49. Middle East and Africa HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Takeda Pharmaceuticals Corporation Information
Table 51. Takeda Pharmaceuticals Description and Major Businesses
Table 52. Takeda Pharmaceuticals Product Models, Descriptions and Specifications
Table 53. Takeda Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Takeda Pharmaceuticals Sales Value Proportion by Product in 2024
Table 55. Takeda Pharmaceuticals Sales Value Proportion by Application in 2024
Table 56. Takeda Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 57. Takeda Pharmaceuticals HAE Treatments SWOT Analysis
Table 58. Takeda Pharmaceuticals Recent Developments
Table 59. BioCryst Pharmaceuticals Corporation Information
Table 60. BioCryst Pharmaceuticals Description and Major Businesses
Table 61. BioCryst Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. BioCryst Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. BioCryst Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. BioCryst Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. BioCryst Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. BioCryst Pharmaceuticals HAE Treatments SWOT Analysis
Table 67. BioCryst Pharmaceuticals Recent Developments
Table 68. CSL Behring Corporation Information
Table 69. CSL Behring Description and Major Businesses
Table 70. CSL Behring Product Models, Descriptions and Specifications
Table 71. CSL Behring Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. CSL Behring Sales Value Proportion by Product in 2024
Table 73. CSL Behring Sales Value Proportion by Application in 2024
Table 74. CSL Behring Sales Value Proportion by Geographic Area in 2024
Table 75. CSL Behring HAE Treatments SWOT Analysis
Table 76. CSL Behring Recent Developments
Table 77. Pharming Healthcare Corporation Information
Table 78. Pharming Healthcare Description and Major Businesses
Table 79. Pharming Healthcare Product Models, Descriptions and Specifications
Table 80. Pharming Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Pharming Healthcare Sales Value Proportion by Product in 2024
Table 82. Pharming Healthcare Sales Value Proportion by Application in 2024
Table 83. Pharming Healthcare Sales Value Proportion by Geographic Area in 2024
Table 84. Pharming Healthcare HAE Treatments SWOT Analysis
Table 85. Pharming Healthcare Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. HAE Treatments Product Picture
Figure 2. Global HAE Treatments Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. C1 Esterase Inhibitors Product Picture
Figure 4. Kallikrein Inhibitors Product Picture
Figure 5. Bradykinin Receptor Antagonist Product Picture
Figure 6. Global HAE Treatments Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital and Clinic
Figure 8. Pharmacy
Figure 9. Other
Figure 10. HAE Treatments Report Years Considered
Figure 11. Global HAE Treatments Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 13. Global HAE Treatments Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global HAE Treatments Revenue Market Share by Region (2020-2031)
Figure 15. Global HAE Treatments Sales (2020-2031) & (K Units)
Figure 16. Global HAE Treatments Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global HAE Treatments Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers HAE Treatments Sales Volume Market Share in 2024
Figure 19. Global HAE Treatments Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. C1 Esterase Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 22. Kallikrein Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 23. Bradykinin Receptor Antagonist Revenue Market Share by Manufacturer in 2024
Figure 24. Global HAE Treatments Sales Market Share by Type (2020-2031)
Figure 25. Global HAE Treatments Revenue Market Share by Type (2020-2031)
Figure 26. Global HAE Treatments Sales Market Share by Application (2020-2031)
Figure 27. Global HAE Treatments Revenue Market Share by Application (2020-2031)
Figure 28. North America HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 29. North America HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 31. North America HAE Treatments Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America HAE Treatments Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 36. Canada HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 38. Europe HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 39. Europe HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 41. Europe HAE Treatments Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 46. France HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 48. Italy HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 49. Russia HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific HAE Treatments Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific HAE Treatments Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 58. Japan HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 61. India HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America HAE Treatments Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa HAE Treatments Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 82. HAE Treatments Industry Chain Mapping
Figure 83. Regional HAE Treatments Manufacturing Base Distribution (%)
Figure 84. Global HAE Treatments Production Market Share by Region (2020-2031)
Figure 85. HAE Treatments Production Process
Figure 86. Regional HAE Treatments Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Table 1. Global HAE Treatments Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global HAE Treatments Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global HAE Treatments Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global HAE Treatments Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global HAE Treatments Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global HAE Treatments Sales by Region (2020-2025) & (K Units)
Table 8. Global HAE Treatments Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global HAE Treatments Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global HAE Treatments Sales Share by Manufacturers (2020-2025)
Table 12. Global HAE Treatments Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global HAE Treatments Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global HAE Treatments by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HAE Treatments as of 2024)
Table 16. Global HAE Treatments Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global HAE Treatments Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers HAE Treatments Manufacturing Base and Headquarters
Table 19. Global HAE Treatments Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global HAE Treatments Sales by Type (2020-2025) & (K Units)
Table 23. Global HAE Treatments Sales by Type (2026-2031) & (K Units)
Table 24. Global HAE Treatments Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global HAE Treatments Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global HAE Treatments ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global HAE Treatments Sales by Application (2020-2025) & (K Units)
Table 29. Global HAE Treatments Sales by Application (2026-2031) & (K Units)
Table 30. HAE Treatments High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global HAE Treatments Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global HAE Treatments Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global HAE Treatments ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America HAE Treatments Growth Accelerators and Market Barriers
Table 37. North America HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe HAE Treatments Growth Accelerators and Market Barriers
Table 40. Europe HAE Treatments Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific HAE Treatments Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific HAE Treatments Growth Accelerators and Market Barriers
Table 45. Southeast Asia HAE Treatments Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America HAE Treatments Investment Opportunities and Key Challenges
Table 47. Central and South America HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa HAE Treatments Investment Opportunities and Key Challenges
Table 49. Middle East and Africa HAE Treatments Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Takeda Pharmaceuticals Corporation Information
Table 51. Takeda Pharmaceuticals Description and Major Businesses
Table 52. Takeda Pharmaceuticals Product Models, Descriptions and Specifications
Table 53. Takeda Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Takeda Pharmaceuticals Sales Value Proportion by Product in 2024
Table 55. Takeda Pharmaceuticals Sales Value Proportion by Application in 2024
Table 56. Takeda Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 57. Takeda Pharmaceuticals HAE Treatments SWOT Analysis
Table 58. Takeda Pharmaceuticals Recent Developments
Table 59. BioCryst Pharmaceuticals Corporation Information
Table 60. BioCryst Pharmaceuticals Description and Major Businesses
Table 61. BioCryst Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. BioCryst Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. BioCryst Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. BioCryst Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. BioCryst Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. BioCryst Pharmaceuticals HAE Treatments SWOT Analysis
Table 67. BioCryst Pharmaceuticals Recent Developments
Table 68. CSL Behring Corporation Information
Table 69. CSL Behring Description and Major Businesses
Table 70. CSL Behring Product Models, Descriptions and Specifications
Table 71. CSL Behring Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. CSL Behring Sales Value Proportion by Product in 2024
Table 73. CSL Behring Sales Value Proportion by Application in 2024
Table 74. CSL Behring Sales Value Proportion by Geographic Area in 2024
Table 75. CSL Behring HAE Treatments SWOT Analysis
Table 76. CSL Behring Recent Developments
Table 77. Pharming Healthcare Corporation Information
Table 78. Pharming Healthcare Description and Major Businesses
Table 79. Pharming Healthcare Product Models, Descriptions and Specifications
Table 80. Pharming Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Pharming Healthcare Sales Value Proportion by Product in 2024
Table 82. Pharming Healthcare Sales Value Proportion by Application in 2024
Table 83. Pharming Healthcare Sales Value Proportion by Geographic Area in 2024
Table 84. Pharming Healthcare HAE Treatments SWOT Analysis
Table 85. Pharming Healthcare Recent Developments
Table 86. Key Raw Materials Distribution
Table 87. Raw Materials Key Suppliers
Table 88. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 89. Milestones in Production Technology Evolution
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. HAE Treatments Product Picture
Figure 2. Global HAE Treatments Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. C1 Esterase Inhibitors Product Picture
Figure 4. Kallikrein Inhibitors Product Picture
Figure 5. Bradykinin Receptor Antagonist Product Picture
Figure 6. Global HAE Treatments Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital and Clinic
Figure 8. Pharmacy
Figure 9. Other
Figure 10. HAE Treatments Report Years Considered
Figure 11. Global HAE Treatments Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 13. Global HAE Treatments Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global HAE Treatments Revenue Market Share by Region (2020-2031)
Figure 15. Global HAE Treatments Sales (2020-2031) & (K Units)
Figure 16. Global HAE Treatments Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global HAE Treatments Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers HAE Treatments Sales Volume Market Share in 2024
Figure 19. Global HAE Treatments Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. C1 Esterase Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 22. Kallikrein Inhibitors Revenue Market Share by Manufacturer in 2024
Figure 23. Bradykinin Receptor Antagonist Revenue Market Share by Manufacturer in 2024
Figure 24. Global HAE Treatments Sales Market Share by Type (2020-2031)
Figure 25. Global HAE Treatments Revenue Market Share by Type (2020-2031)
Figure 26. Global HAE Treatments Sales Market Share by Application (2020-2031)
Figure 27. Global HAE Treatments Revenue Market Share by Application (2020-2031)
Figure 28. North America HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 29. North America HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 31. North America HAE Treatments Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America HAE Treatments Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 36. Canada HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 38. Europe HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 39. Europe HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 41. Europe HAE Treatments Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 46. France HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 48. Italy HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 49. Russia HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific HAE Treatments Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific HAE Treatments Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 58. Japan HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 61. India HAE Treatments Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America HAE Treatments Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa HAE Treatments Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa HAE Treatments Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers HAE Treatments Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa HAE Treatments Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America HAE Treatments Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa HAE Treatments Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa HAE Treatments Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa HAE Treatments Revenue (2020-2025) & (US$ Million)
Figure 82. HAE Treatments Industry Chain Mapping
Figure 83. Regional HAE Treatments Manufacturing Base Distribution (%)
Figure 84. Global HAE Treatments Production Market Share by Region (2020-2031)
Figure 85. HAE Treatments Production Process
Figure 86. Regional HAE Treatments Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232